Clinical Trial Update: Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases [Phase 2]

View source ↗

Summary

A Phase 2 pembrolizumab trial in untreated B-cell non-Hodgkin lymphoproliferative diseases has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Indolent B-cell Non-hodgkin Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Washington | Conditions: Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2022-12-30